Frequency and risk factors for extraintestinal manifestations in the swiss inflammatory bowel disease cohort

American Journal of Gastroenterology

Volumn 106, Issue 1, 2011, Pages 110-119

  Vavricka, Stephan R ^a   Brun, Lionel ^a   Ballabeni, Pierluigi ^b   Pittet, Valérie ^b   Prinz Vavricka, Bettina Mareike ^c   Zeitz, Jonas ^a   Rogler, Gerhard ^a   Schoepfer, Alain M ^d,e  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c Private Practice   (Switzerland)

^d MCMASTER UNIVERSITY   (Canada)

^e UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANKYLOSING SPONDYLITIS; APHTHOUS STOMATITIS; ARTHRITIS; ARTICLE; CROHN DISEASE; ENTERITIS; ERYTHEMA NODOSUM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PSORIASIS; PYODERMA GANGRENOSUM; RISK FACTOR; SWITZERLAND; ULCERATIVE COLITIS; UVEITIS;

ADULT; AGE DISTRIBUTION; AGE OF ONSET; ARTHRITIS; COHORT STUDIES; COLITIS, ULCERATIVE; CONFIDENCE INTERVALS; CROHN DISEASE; ERYTHEMA NODOSUM; FEMALE; HUMANS; INCIDENCE; INFLAMMATORY BOWEL DISEASES; LIVER DISEASES; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PROGNOSIS; PROSPECTIVE STUDIES; PSORIASIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; SPONDYLITIS, ANKYLOSING; SWITZERLAND; UVEITIS;

EID: 78650988140     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2010.343     Document Type: Article

References (42)

1. Das KM. Relationship of extraintestinal involvements in inflammatory bowel disease: new insights into autoimmune pathogenesis. Dig Dis Sci 1999; 44: 1-13. Review.
2. Monsén U, Sorstad J, Hellers G et al. Extracolonic diagnoses in ulcerative colitis: an epidemiological study. Am J Gastroenterol 1990; 85: 711-6.
3. Danese S, Semeraro S, Papa A et al. Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol 2005; 11: 7227-36. Review.
4. Bernstein CN, Blanchard JF, Rawsthorne P et al. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol 2001; 96: 1116-22.
5. Ricart E, Panaccione R, Loft us EV Jr et al. Autoimmune disorders and extraintestinal manifestations in first-degree familial and sporadic inflammatory bowel disease. Inflamm Bowel Dis 2004; 10: 207-14.
6. Mendoza JL, Lana R, Taxonera C et al. Extraintestinal manifestations in inflammatory bowel disease: differences between Crohn's disease and ulcerative colitis. Med Clin (Barc) 2005; 125: 297-300.
7. Rankin GB, Watts HD, Melnyk CS et al. National Cooperative Crohn' s disease study: extraintestinal manifestations and perianal complications. Gastroenterology 1979; 77: 914-20.
8. Su CG, Judge TA, Lichtenstein GR. Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Clin North Am 2002; 31: 307-27.
9. Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients. Medicine 1976; 55: 401-12.
10. Farmer RG, Hawk WA, Turnbull RB Jr. Clinical patterns in Crohn's disease: a statistical study of 615 cases. Gastroenterology 1975; 68: 627-35.
11. Veloso FT, Carvalho J, Magro F. Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. J Clin Gastroenterol 1996; 23: 29-34.
12. Kethu SR. Extraintestinal manifestations of inflammatory bowel diseases. J Clin Gastroenterol 2006; 40: 467-75. Review.
13. Barrie A, Regueiro M. Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis 2007; 13: 1424-9.
14. Trost LB, McDonnell JK. Important cutaneous manifestations of inflammatory bowel disease. Postgrad Med J 2005; 81: 580-5.
15. Levitt M, Ritchie J, Lennard-Jones J et al. Pyoderma gangrenosum in inflammatory bowel disease. Br J Surg 1991; 78: 676-8.
16. Mir-Madjlessi SH, Taylor JS, Farmer RG. Clinical course and evolution of erythema nodosum and pyoderma gangrenosum in chronic ulcerative colitis: a study of 42 patients. Am J Gastroenterol 1985; 80: 615-20.
17. White JW. Erythema nodosum. Dermatol Clin 1985; 3: 119-27.
18. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989; 170: 2-6.
19. Pittet V, Juillerat P, Mottet C et al. Cohort profile: the Swiss inflammatory Bowel Disease Cohort Study (SIBDCS). Int J Epidemiol 2009; 38: 922-31.
20. Juillerat P, Mottet C, Pittet V et al. Extraintestinal manifestations of Crohn's disease. Digestion 2007; 76: 141-8.
21. Cohen AD, Dreiher J, Birkenfeld S. Psoriasis associated with ulcerative colitis and Crohn's disease. J Eur Acad Dermatol Venereol 2009; 23: 561-5.
22. Nair R, Henseler T, Jenisch S et al. Evidence for two psoriasis susceptibility loci (HLA and 17q) and two novel candidate regions (16q and 20p) by genome-wide scan. Hum Mol Genet 1997; 6: 1349-56.
23. Najarian DJ, Gottlieb AB. Connections between psoriasis and Crohn's disease. J Am Acad Dermatol 2003; 48: 805-21.
24. Silverberg MS, Satsangi J, Ahmad T et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005; 19 (Suppl A): 5-36.
25. Stange EF, Travis SPL, Vermeire S et al. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut 2006; 55 (Suppl1): i1-15.
26. Lichtiger S, Present DH. Preliminary report: cyclosporin in treatment of severe active ulcerative colitis. Lancet 1990; 336: 16-9.
27. D'Haens G, Sandborn WJ, Feagan BG et al. A review of activity indices and Efficacy and points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007; 132: 763-86.
28. Jiang L, Xia B, Li J et al. Retrospective survey of 452 patients with inflammatory bowel disease in Wuhan city, central China. Inflamm Bowel Dis 2006; 12: 212-7.
29. Oshitani N, Watanabe K, Nakamura S et al. Extraintestinal complications in patients with ulcerative colitis. Nippon Rinsho 2005; 63: 874-8.
30. Orchard TR, Wordsworth BP, Jewell DP. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut 1998; 42: 387-91.
31. De Vlam K, Mielants H, Cuvelier C et al. Spondylarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association. J Rheumatol 2000; 27: 2860-5.
32. Yüksel I, Basar O, Ataseven H et al. Mucocutaneous manifestations in inflammatory bowel disease. Inflamm Bowel Dis 2009; 15: 546-50.
33. McCullough MJ, Abdel-Hafeth S, Scully C. Recurrent aphthous stomatitis revisited; clinical features, associations, and new association with infant feeding practices? J Oral Pathol Med 2007; 36: 615-20.
34. Yates VM, Watkinson G, Kelman A. Further evidence for an association between psoriasis, Crohn's disease and ulcerative colitis. Br J Dermatol 1982; 106: 323-30.
35. Petrelli EA, McKinley M, Troncale FJ. Ocular manifestations of inflammatory bowel disease. Ann Ophthalmol 1982; 14: 356-60.
36. Oisson R, Danielsson A, J. rnerot G et al. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology 1991; 100: 1319-23.
37. Rasmussen HH, Fallingborg JF, Mortensen PB et al. Hepatobiliary dysfunction and primary sclerosing cholangitis in patients with Crohn's disease. Scand J Gastroenterol 1997; 32: 604-10.
38. Bhagat S, Das KM. A shared and unique peptide in the human colon, eye, and joint detected by a monoclonal antibody. Gastroenterology 1994; 107: 103-8.
39. Satsangi J, Grootscholten C, Holt H et al. Clinical patterns of familial inflammatory bowel disease. Gut 1996; 38: 738-41.
40. Chapman RW, Varghese Z, Gaul R et al. Association of primary sclerosing cholangitis with HLA-B8. Gut 1983; 24: 38-41.
41. Roussomoustakaki M, Satsangi J, Welsh K et al. Genetic markers may predict disease behaviour in patients with ulcerative colitis. Gastroenterology 1997; 112: 1845-53.
42. Juillerat P, Pittet V, Bulliard JL et al. Prevalence of IBD in the canton of Vaud (Switzerland): a population-based cohort study. J Crohn's Colitis 2008; 2: 131-41.